Press kit

A selection of the Owkin team


Owkin is the first full-stack TechBio company on a mission to understand complex biology and derive new multimodal biomarkers through AI.

We identify precision therapeutics, de-risk and accelerate clinical trials and develop diagnostics using AI trained on world-class patient data through privacy-enhancing technologies. We merge wet lab experiments with advanced AI techniques to create a powerful feedback loop for accelerated discovery and innovation in oncology, cardiovascular, immunity and inflammation.

Owkin also founded MOSAIC, the world’s largest spatial multi-omics atlas for cancer research across seven cancer indications.

Owkin has raised over $300 million through investments from leading biopharma companies, including Sanofi and BMS, and venture funds like Fidelity, GV and Bpifrance, among others.

Media contact

Owkin’s experts are available to comment on topics related to medical research and Al.

For international media requests, please contact

For French media requests, please contact

About our founder

Thomas Clozel M.D.
Chief Executive Officer and co-founder

Thomas leads Owkin as CEO. He is a former Assistant Professor of Clinical Onco-Hematology at Hopital Henri Mondor in Paris and former member of Ari Melnick’s lab at the Weill Cornell Medical College. He ensures that patient health is prioritized when developing breakthrough medical technologies, bringing a patient-centric approach to each Owkin project.


Where is Owkin based?
What is Owkin's founding story?
What makes Owkin different?
How does Owkin ensure data privacy and security?
How much investment has Owkin received?